2022³âµµ ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãá°èÇмú´ëȸ : 2022-03-25±³À°ÀÏÀÚ : 2022-03-25
±³À°Àå¼Ò : ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ ¹× ´ëȸÀǽÇ
±³À°ÁÖÁ¦ :
2022³âµµ ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ
´ã´çÀÚ : À̼¼Àº
¿¬¶ôó : 02-784-2742
À̸ÞÀÏ :
secretariat@kcnp.or.kr ±³À°Á¾·ù : Á¤½Å°Ç°ÀÇÇаú
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 12 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í »çÀüµî·Ïºñ Æò»ýȸ¿ø:¸éÁ¦/Á¤È¸¿ø:50,000/ºñȸ¿ø:60,000/ÁØȸ¿ø¹×±âŸ:30,000 ´çÀϵî·Ïºñ Æò»ýȸ¿ø:10,000/Á¤È¸¿ø:60,000/ºñȸ¿ø:80,000/ÁØȸ¿ø¹×±âŸ:40,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-25 ÄÁº¥¼ÇȦ 09:30~09:55 Suicide ÀÌ»ó¹Î(°æÈñÀÇ´ë)
±³À°½Ã°£ 03-25 ÄÁº¥¼ÇȦ 09:55~10:20 Mood disorder ¹®Àº¼ö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 03-25 ÄÁº¥¼ÇȦ 10:20~10:40 Addiction ±èÀå·¡(±¹¸³Áß¾ÓÀÇ·á¿ø)
±³À°½Ã°£ 03-25 ´ëȸÀÇ½Ç 09:30~09:55 Unipolar disorder vs bipolar disorder ÀüÈ«ÁØ(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 03-25 ´ëȸÀÇ½Ç 09:55~10:20 Schizophrenia vs personality disorder ÀÌÁ¤¼®(±¹¹Î°Ç°º¸ÇèÀϻ꺴¿ø)
±³À°½Ã°£ 03-25 ´ëȸÀÇ½Ç 10:20~10:40 Organic mood disorder vs non-organic mood disorder ÀÓÀº¼º(½Å¼¼°èÈ¿º´¿ø)
ÈÞ½Ä 03-25 10:10~10:55 ()
±³À°½Ã°£ 03-25 ÄÁº¥¼ÇȦ 10:55~11:20 Immune system and depression ½Å»óÈ£(°í·ÁÀÇ´ë)
±³À°½Ã°£ 03-25 ÄÁº¥¼ÇȦ 11:20~11:45 Anti-inflammatory agents ³ë´ë¿µ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 03-25 ÄÁº¥¼ÇȦ 11:45~12:05 Repurposing drugs (ketamine, anti-diabetic, etc.) ±è¼±¹Ì(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 03-25 ´ëȸÀÇ½Ç 10:55~11:20 Neurobiology of psychedelic drugs ¿ÀÈ«¼®(°Ç¾çÀÇ´ë)
±³À°½Ã°£ 03-25 ´ëȸÀÇ½Ç 11:20~11:45 MDMA and psychedelic-assisted psychotherapy ³ªÀÇÇö(¿¹¼öº´¿ø)
±³À°½Ã°£ 03-25 ´ëȸÀÇ½Ç 11:45~12:05 Psilocybin °ÇÑ°íÀººñ(±¹¸³³ªÁÖº´¿ø)
±³À°½Ã°£ 03-25 ÄÁº¥¼ÇȦ 12:05~12:35 A paradigm shift to recover from depression Àå½ÂÈ£(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 03-25 ÄÁº¥¼ÇȦ 12:35~13:05 Therapeutic advantage of Agomelatine in treating depression ¼Á¤¼®(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 03-25 ´ëȸÀÇ½Ç 12:05~12:35 Building best SPRAVATO clinical practice for TRD patients Á¤¿µÀº(Á¦ÁÖÀÇ´ë)
±³À°½Ã°£ 03-25 ´ëȸÀÇ½Ç 12:35~13:05 New community care model(CCM) with SPRAVATO ¾çÂù¸ð(¿ø±¤ÀÇ´ë)
ÈÞ½Ä 03-25 13:05~13:20 ()
±³À°½Ã°£ 03-25 ÄÁº¥¼ÇȦ 13:20~13:45 Manic/hypomanic and depressive episode ¿ì¿µ¼·(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-25 ÄÁº¥¼ÇȦ 13:45~14:10 Mixed features and maintenance therapy ÀÌÁ¤±¸(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 03-25 ÄÁº¥¼ÇȦ 14:10~14:30 Rapid cycling and pharmacotherapy of special populations Á¤Á¾Çö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-25 ´ëȸÀÇ½Ç 13:20~13:55 Emotional blunting and anhedonia management Á¤¸íÈÆ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 03-25 ´ëȸÀÇ½Ç 13:55~14:30 Complexities in the management of elderly patients with MDD ¿Õ¼º¹Î(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-25 ÄÁº¥¼ÇȦ 14:30~15:20 ¸ÞŸ¹ö½º¿¡ º´¿øÀ» ÁþÀÚ ÃÖ¿ì½Ä(µö³ëÀ̵å)
ÈÞ½Ä 03-25 15:20~15:30 ()
±³À°½Ã°£ 03-25 ÄÁº¥¼ÇȦ 15:30~15:55 Cholinesterase + Memantine for dementia ÀÌÁØ¿µ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03-25 ÄÁº¥¼ÇȦ 15:55~16:20 Methylphenidate + Atomoxetine for adult ADHD ¼ºÇü¸ð(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 03-25 ÄÁº¥¼ÇȦ 16:20~16:40 Long-acting injectable antipsychotics + AAP for schizophrenia ¹Ú¼º¿ë(°è¿äº´¿ø)
±³À°½Ã°£ 03-25 ´ëȸÀÇ½Ç 15:30~15:55 Current drug (AAP, Cariprazine, etc.) È«Á¤¿Ï(Àͻ꺴¿ø)
±³À°½Ã°£ 03-25 ´ëȸÀÇ½Ç 15:55~16:20 New drugs 1: Xanomeline-trospium, Ulotaront Àå¿ÁÁø(±¹¸³ºÎ°îº´¿ø)
±³À°½Ã°£ 03-25 ´ëȸÀÇ½Ç 16:20~16:40 New drugs 2: Roluperidone, Pimavanserin ¹Ú¿µ¹Î(ÀÎÁ¦ÀÇ´ë)